SRZN

In October 2026, Surrozen announced FDA clearance of its IND application for SZN-8141 for diabetic macular edema, allowing it to advance into clinical development and meeting a milestone for new funding. This followed the submission of the IND application in September 2026. In August 2026, the company reported its Second Quarter 2026 Financial Results, swinging to a $50.2 million profit due to Boehringer milestone revenue, and Surrozen warrants expiring in 2026 were removed from Nasdaq listing. The First Quarter 2026 Financial Results were reported in May 2026. Over the past three months, company insiders, including CEO Craig Parker, COO Charles Williams, and VP Yang Li, have sold shares. The stock has experienced significant positive changes, with a 1-month change of +28% and a 1-year change of +112.9% as of early October 2026.